Veterinary Medicines Directorate

United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS

NATIONAL PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Alpramil 12 mg/30 mg Film-Coated Tablets for Cats
Alpramil 16 mg/40 mg Film-Coated Tablets for Cats
Alpramil 4 mg/10 mg Film-Coated Tablets for Cats

Date Created: July 2022

MODULE 1

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Alpramil Film-Coated Tablets for Cats; 12 mg/30 mg, 16 mg/40 mg, 4 mg/10 mg
Applicant	Alfasan Nederland BV Kuipersweg 9 3449 JA Woerden The Netherlands
Active substance	Milbemycin Oxime (A3 and A4) Praziquantel
ATC Vetcode	QP54AB51
Target species	Cats
Indication for use	Treatment of mixed infections by immature and adult cestodes and nematodes of the following species: - Cestodes: • *Dipylidium caninum* • *Taenia spp.* • *Echinococcus multilocularis* - Nematodes: • *Ancylostoma tubaeforme* • *Toxocara cati* Prevention of heartworm disease (*Dirofilaria immitis*) if concomitant treatment against cestodes is indicated.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

(www.gov.uk/check-animal-medicine-licensed)

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Alpramil 16/40mg: Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended. Alpramil 4/10mg and 12/30mg: Generic hybrid application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	17/2/2022

I. SCIENTIFIC OVERVIEW

Alpramil 16/40mg:

The quality / safety / efficacy aspects of this product are identical to Milbemax film coated tablets for cats. The initial application for Milbemax was assessed before there was a requirement to have a public assessment report, therefore no details in this section are available.

Alpramil 4/10mg and 12/30mg:

This was determined a generic 'hybrid' application because of a quantitative change to the active substances with regard to the reference medicinal product have been made.

II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

II.A. Composition

The product contains milbemycin oxime and praziquantel and the excipients titanium dioxide (E171), quinoline yellow (E104), sunset yellow (E110), povidone, microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, colloidal hydrated silica, magnesium stearate, hypromellose, macrogol, vanillin, iron oxide yellow (E172) and iron oxide red (E172).

The choice of the formulation and the absence of preservative are justified.

The product is an established pharmaceutical form, and its development is adequately described in accordance with the relevant European guidelines.

The packaging consists of PVC/PE/PVDC/aluminium blister packs.

II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of wet granulation, compression and film coating.

The product is manufactured in accordance with the European Pharmacopoeia and relevant European guidelines.

II.C. Control of Starting Materials

The active substances are milbemycin oxime and praziquantel and are both established active substances described in the European Pharmacopoeia. The active substances are manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

II.C.4. Substances of Biological Origin

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

The tests performed during production were described and the results of 3 consecutive runs, conforming to the specifications, were provided.

II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification.

II.F. Stability

The active substance is fully tested to ensure compliance with its specification immediately prior to its use in manufacture of the product.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 2 years
Shelf life of divided tablets after first opening the immediate packaging: 7 days

III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACO-TOXICOLOGICAL)

III.A Safety Documentation

Pharmacological Studies

The applicant submitted a pilot and a pivotal bioequivalence study between the 16/40 mg test product and the reference product. Due to the legal basis of the application, further studies for the additional tablet strengths were exempted.

Toxicological Studies

No data required.

User Safety

A user risk assessment was provided in compliance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:,

- In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.
- Wash hands after use.

Environmental Safety

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

Phase I:

The product will only be used in non-food animals and as a result environmental exposure will be low. A Phase II ERA was not required.

IV. CLINICAL DOCUMENTATION

IV.I. Pre-Clinical Studies

Pharmacokinetics

The applicant has submitted a pilot and pivotal bioequivalence study between the 16/40 mg test product and the reference product. An *in vivo* bioequivalence study to demonstrate bioequivalence between the test and reference products is considered appropriate for both actives. Bioequivalence was established. The applicant also conducted an *in vivo* study to claim an exemption from conducting further studies with the additional tablet strengths which suggested the dissolution profiles are similar.

Tolerance in the Target Species

Tolerance studies were not required.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that the benefit/risk profile of the products are favourable.

MODULE 4

POST- AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)